Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Clin Exp Ophthalmol. 2022 Jun 30;50(7):803–805. doi: 10.1111/ceo.14125

Figure 2:

Figure 2:

Reporting of significant vision loss following intravitreal aflibercept injection. Almost twice as many ophthalmologists reported at least 1 episode of significant vision loss with aflibercept PFS use (51/76, 67%) when compared to the vial preparation (27/76, 35%).